With an ever growing demand for biologic therapeutics in the Pharmaceutical Industry, this year's programme has been tailored for an audience of professionals working in immunogenicity from drug design through to clinical development and clinical trials.
Conference highlights include a keynote address from Martin Lechmann, Development DMPK Project Leader from Roche. The presentation entitled: Insight into the Development of Biological Therapeutics will discuss the main principles of immunogenicity testing during product development and will also be reviewing the pharmacokinetic effects of biological therapeutics.
The opening address at the Immunogenicity conference will be made by Melody Sauerborn, Senior Immunogenicity Expert from TNO Triskelion. When asked about the event she commented:
"This conference offers a very broad selection of topics in addition to very well-known names in the field of immunogenicity”
“My presentation and workshop aims at delivering the fundaments in immunology and immunogenicity to the audience so they are all on the same page and their knowledge and mains refreshed on the topic of immunogenicity to fully appreciate and fully take in the other presentations and topics”
A snap shot of those who have confirmed attendance include AbbVie, Lonza Biologics, GSK and Swedish Orphan Biovitrum
Further interview with key speakers are available to download online at
14-15 July 2014
Holiday Inn Regents Park
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
More information can be found at http://www.smi-